SequelSEC

Aurinia Pharmaceuticals Inc. AUPH

Pharmaceutical Preparations · CIK 0001600620 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$311.51M
Fiscal year ended 2026-06-30
Operating income
$150.75M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $311.51M and net income of $314.11M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Aurinia Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aurinia Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$311.51M
Cost of revenue$30.04M
Gross profit$281.47M
Operating income$150.75M
Net income$314.11M
Research & development$39.85M
Weighted-average diluted sharesUnavailable
Pretax income$160.36M
Income tax expense-$153.75M
Diluted EPS$2.29
Selling, general & administrativeUnavailable
General & administrative$100.97M
Selling & marketingUnavailable

Balance

Aurinia Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$179.73M
Total assets$792.26M
Current assets$541.32M
Total liabilities$177.40M
Current liabilities$99.89M
Total equity incl. NCI$614.86M
Temporary (mezzanine) equityUnavailable
Inventory$45.15M
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.74M

Cash flow

Aurinia Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$175.24M
Capital expendituresUnavailable
Investing cash flow$12.84M
Financing cash flow-$61.25M
Net change in cash$126.83M
Stock-based compensation$14.62M
Common dividends paidUnavailable
Common share repurchases$83.55M
Depreciation & amortization$19.38M

Derived

Aurinia Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin90.4%
Operating margin48.4%
FCF marginUnavailable
SBC / revenue4.7%
Current ratio5.42x
Revenue YoY growth19.8%
Net margin100.8%
R&D / revenue12.8%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rate-95.9%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AUPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.